Early cancer drug trial halted before key testing phase

NCT ID NCT05252390

Summary

This early-stage study tested a new oral cancer drug called NUV-868, both alone and combined with existing medications (olaparib or enzalutamide), in adults with advanced solid tumors. The trial aimed to find safe doses and see if these treatments could help control cancers that had stopped responding to standard therapies. However, the study was terminated before reaching the main effectiveness testing phase.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cabrini Hospital Malvern

    Malvern, Victoria, 3144, Australia

  • Calvary Mater Hospital Newcastle

    Waratah, New South Wales, 2298, Australia

  • Carolina BioOncology Institute

    Huntersville, North Carolina, 28078, United States

  • Ellison Institute of Technology

    Los Angeles, California, 90064, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Laura & Isaac Perlmutter Cancer Center - NYU Langone Health

    New York, New York, 10016, United States

  • Linear Clinical Research

    Nedlands, Western Australia, 6009, Australia

  • Macquarie University Hospital

    North Ryde, New South Wales, 2109, Australia

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • NEXT Virginia

    Fairfax, Virginia, 22031, United States

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Rocky Mountain Cancer Centers, LLP

    Aurora, Colorado, 80012, United States

  • Rocky Mountain Cancer Centers, LLP

    Lone Tree, Colorado, 80124, United States

  • Sarah Cannon Research Institute - Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21231, United States

  • Texas Oncology - Fort Worth Cancer Center

    Fort Worth, Texas, 76104, United States

  • The University of Arizona Cancer Center

    Tucson, Arizona, 85724, United States

  • Virginia Oncology Associates

    Norfolk, Virginia, 23502, United States

Conditions

Explore the condition pages connected to this study.